Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

GAT100

Covalent probe of the CB1 allosteric site: a negative modulator more potent than Org27569, without inverse agonism.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₅H₂₈N₄OS

CAS 1663564-42-8

Family
ECS pharmacological toolAllosteric modulator
Molar mass
432.60 g/mol

Updated on

In plain terms

GAT100 does not activate the CB1 receptor and does not sit on the site targeted by cannabinoids: it binds elsewhere on the receptor and dampens its response. It attaches irreversibly, which makes it a laboratory tool for mapping this second site. It has been studied only in cells; no study in humans was found.

Receptors and activity

Target network

CB1 (allosteric site)Negative allosteric modulatorCovalent negative allosteric modulator of the signalling induced by CP55,940, 2-AG and anandamide (β-arrestin 1, PLCβ3, ERK1/2, cAMP, internalisation); potentiates [3H]CP55,940 binding; without inverse agonism; no numerical value in the abstracts (Laprairie et al. 2016; Kulkarni et al. 2016)
  • Blocks or inhibits

The lower the cited value, the closer the target sits to GAT100: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of GAT100.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1 (allosteric site)Negative allosteric modulatorno measured value cited

    Covalent negative allosteric modulator of the signalling induced by CP55,940, 2-AG and anandamide (β-arrestin 1, PLCβ3, ERK1/2, cAMP, internalisation); potentiates [3H]CP55,940 binding; without inverse agonism; no numerical value in the abstracts (Laprairie et al. 2016; Kulkarni et al. 2016)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

GAT100 is a covalent probe of the allosteric site of the CB1 receptor. Kulkarni and colleagues described in 2016 the first ligands designed to bind irreversibly to this site, by introducing an electrophilic or photoactivatable group into Org27569 and PSNCBAM-1, two reference negative allosteric modulators; compound 20, GAT100, emerged as the most potent in functional assays, without inverse agonism, and it also potentiated CP55,940 binding. Laprairie and colleagues profiled it across five downstream pathways (β-arrestin 1 recruitment, phospholipase C β3 and ERK1/2 phosphorylation, cAMP accumulation, CB1 internalisation): it dampens the response to CP55,940, 2-arachidonoylglycerol and anandamide, in three cell systems of which two express CB1 endogenously, with greater potency and efficacy than Org27569 and PSNCBAM-1. Modelling identifies cysteine C7.38(382) as a key element of its binding. This work concerns cells and membranes; no study in animals or humans was found.

History

Source
An entirely synthetic compound, with no natural occurrence found. It is described as a covalent pharmacological probe intended to map the allosteric site of the CB1 receptor (Kulkarni et al. 2016); no clinical use was found.

Origin

Research tool

No biological pathway: GAT100 is a synthetic compound, an indole-2-carboxamide derivative of Org27569 bearing an isothiocyanate group, unrelated to the plant cannabinoid pathway.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Allosteric modulator

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

GAT100 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
3-ethyl-5-isothiocyanato-N-[2-(4-piperidin-1-ylphenyl)ethyl]-1H-indole-2-carboxamide
Other names
GAT-100 · GAT 100

Identifiers

Formula
C₂₅H₂₈N₄OS
CAS
1663564-42-8
InChIKey
YIYLMDVRSNXYOT-UHFFFAOYSA-N
SMILES
CCC1=C(NC2=C1C=C(C=C2)N=C=S)C(=O)NCCC3=CC=C(C=C3)N4CCCCC4

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.